Verona Pharma plc
PDMR Dealing
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name
|
Dr. Jan-Anders Karlsson |
||||||
|
2 |
Reason for the notification |
|||||||
|
|
|
Chief Executive Officer |
||||||
|
b) |
Initial notification/Amendment
|
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Verona Pharma plc |
||||||
|
b) |
LEI
|
n/a |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 5 pence each GB00BYW2KH80 |
||||||
|
b) |
Nature of the transaction
|
Jan-Anders Karlsson purchased 19,750 Ordinary Shares |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d) |
Aggregated information - Aggregated volume - Price
|
19,750 Ordinary Shares at 149 pence per Ordinary Share
|
||||||
|
e) |
Date of the transaction |
12,000 Ordinary Shares on 28 February 2017 and 7,750 Ordinary Shares on 1 March 2017 |
||||||
|
f) |
Place of the transaction
|
London Stock Exchange, AIM |
||||||